| Literature DB >> 9674825 |
P A Calabresi1, N S Fields, H W Maloni, A Hanham, J Carlino, J Moore, M C Levin, S Dhib-Jalbut, L R Tranquill, H Austin, H F McFarland, M K Racke.
Abstract
Transforming growth factor (TGF)-beta2 is a pleiotropic cytokine associated with remissions in multiple sclerosis (MS) and amelioration of allergic encephalomyelitis. We assessed the safety of TGF-beta2 in an open-label trial of 11 patients with secondary progressive (SP) MS. Five patients had a reversible decline in the glomerular filtration rate. There was no change in expanded disability status scale or MRI lesions during treatment. Systemic TGF-beta2 may be associated with reversible nephrotoxicity, and further investigation of its therapeutic potential in MS should be performed with caution.Entities:
Mesh：
Substances：
Year: 1998 PMID： 9674825 DOI： 10.1212/wnl.51.1.289
Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910